SCHEMBL7815859

SCHEMBL7815859

O=C1c2ccccc2C(=O)c2oc(-c3ccc(F)cc3)nc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP1 O94782 6/20 1.00
USP19 O94966 2/20 1.00
UCHL3 P15374 1/20 1.00
WDR48 Q8TAF3 2/20 0.77
USP8 P40818 3/20 0.62
OTUB1 Q96FW1 3/20 0.62
USP36 Q9P275 3/20 0.62
USP2 O75604 2/20 0.62
MAPK14 Q16539 3/20 0.47
MAPT P10636 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
ALDH1A1 P00352 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
MAOB P27338 1/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
MAPK13 O15264 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31276578 1.00 USP1 (1.00) USP1USP19UCHL3WDR48USP8
SCHEMBL7808226 0.87 USP1 (1.00) USP1USP19UCHL3WDR48USP8
SCHEMBL29629183 0.87 USP1 (1.00) USP1USP19UCHL3WDR48USP8
SCHEMBL29629184 0.87 USP1 (1.00) USP1USP19UCHL3WDR48USP8
SCHEMBL7808410 0.85 USP1 (0.77) USP1USP19UCHL3WDR48USP8
SCHEMBL7968066 0.85 USP1 (0.77) USP1USP19UCHL3WDR48USP8
SCHEMBL19225117 0.85 USP1 (0.77) USP1USP19UCHL3WDR48USP8
SCHEMBL19220486 0.84 USP1 (0.82) USP1USP19UCHL3WDR48USP8
SCHEMBL7808446 0.84 USP1 (0.72) USP1USP19UCHL3WDR48USP8
SCHEMBL19198309 0.84 USP1 (0.72) USP1USP19UCHL3WDR48USP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0876356-B1 USE OF TRICYCLIC 1,4-DIHYDRO-1,4-DIOXO-1H-NAPHTHALENE DERIVATIVES, RESULTING NOVEL COMPOUNDS AND THERAPEUTICAL USE THEREOF INNOTHERA SA LAB (FR) 2001-10-31 EP claimed
US-20210186964-A1 METHODS OF TREATING CANCERS DANA-FARBER CANCER INSTITUTE, INC. 2021-06-24 US disclosed
US-10653676-B2 Small molecule inhibitors of USP1 deubiquitinating enzyme activity DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-05-19 US disclosed
US-10450281-B1 Compounds and methods for treating cancer DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-10-22 US disclosed
US-9725425-B1 Compounds and methods for treating cancer DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-08-08 US disclosed
US-20170202810-A1 SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-07-20 US disclosed
US-20170202810-A1 SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-07-20 US disclosed
US-9518032-B2 Small molecule inhibitors of USP1 deubiquitinating enzyme activity DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-12-13 US disclosed
US-9518032-B2 Small molecule inhibitors of USP1 deubiquitinating enzyme activity DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-12-13 US disclosed
US-20130253005-A1 SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2013-09-26 US disclosed
US-20130253005-A1 SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2013-09-26 US disclosed
WO-2011137320-A2 SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY DANA-FARBER CANCER INSTITUTE, INC. (US) 2011-11-03 WO disclosed
EP-0876356-B1 USE OF TRICYCLIC 1,4-DIHYDRO-1,4-DIOXO-1H-NAPHTHALENE DERIVATIVES, RESULTING NOVEL COMPOUNDS AND THERAPEUTICAL USE THEREOF INNOTHERA SA LAB (FR) 2001-10-31 EP disclosed
US-6262095-B1 TREATMENT OF ILLNESS ASSOCIATED WITH AN ALTERATION IN VENOUS FUNCTION AND/OR INFLAMMATORY EDEMA LABORATOIRE INNOTHERA (FR) 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130253005-A1 SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY USP1, USP2, USP28 USP1 1/4885USP19 20/4885UCHL3 33/4885
US-20210186964-A1 METHODS OF TREATING CANCERS BRCA1, TP53, BAP1 USP1 6/4885USP19 89/4885UCHL3 68/4885
US-10450281-B1 Compounds and methods for treating cancer USP8, USP2, NEDD8 USP1 7/4885USP19 22/4885UCHL3 29/4885
US-10653676-B2 Small molecule inhibitors of USP1 deubiquitinating enzyme activity USP1, USP2, USP28 USP1 1/4885USP19 20/4885UCHL3 33/4885
US-20170202810-A1 SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY USP1, USP2, USP28 USP1 1/4885USP19 20/4885UCHL3 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.